Daclizumab, a MS treatment targeting IL2-receptor, has been recently withdrawn following reports of immune-mediated encephalitis. We report the case of a 39-years-old woman treated with daclizumab that presented a progressive decrease in the strength at her lower limbs which further worsened after the drug was stopped. Post-treatment MRI showed more than 20 new enhancing lesions. No symptoms nor signs associated with immune-mediated encephalitis were present. Our case highlights the problem of disease course after daclizumab discontinuation and urge neurologists to strictly monitor patients discontinuing the drug in order to exclude both the occurrence of immune-mediated encephalitis and disease reactivation.
Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation / Martinelli, V.; Dalla Costa, G.; Sangalli, F.; Colombo, B.; Robotti, M.; Moiola, L.; Comi, G.. - In: MULTIPLE SCLEROSIS AND RELATED DISORDERS. - ISSN 2211-0348. - 28:(2019), pp. 57-59. [10.1016/j.msard.2018.11.034]
Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation
Dalla Costa G.;Comi G.
2019-01-01
Abstract
Daclizumab, a MS treatment targeting IL2-receptor, has been recently withdrawn following reports of immune-mediated encephalitis. We report the case of a 39-years-old woman treated with daclizumab that presented a progressive decrease in the strength at her lower limbs which further worsened after the drug was stopped. Post-treatment MRI showed more than 20 new enhancing lesions. No symptoms nor signs associated with immune-mediated encephalitis were present. Our case highlights the problem of disease course after daclizumab discontinuation and urge neurologists to strictly monitor patients discontinuing the drug in order to exclude both the occurrence of immune-mediated encephalitis and disease reactivation.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
